Eisai Co., Ltd. (ESALF) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 Tokyo, 일본. 현재 CEO는 Haruo Naito.
ESALF 을(를) 보유 IPO 날짜 2011-04-07, 11,067 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $8.46B.
Eisai Co., Ltd. is a Tokyo-based pharmaceutical company founded in 1941 that develops and markets a diverse portfolio of prescription and over-the-counter products across multiple therapeutic areas. The company's key branded medications include Aricept for Alzheimer's disease and Lewy body dementia, Fycompa for epilepsy, Dayvigo for insomnia, and Lenvima for various cancers including thyroid, renal cell, and hepatocellular carcinoma. Eisai also markets Halaven for breast cancer and liposarcoma, Lyrica for pain management, Pariet for gastrointestinal disorders, and Humira for autoimmune diseases, alongside consumer health products such as vitamin supplements and designated quasi-drugs. The company serves the Japanese market as a leading player in both prescription pharmaceuticals and consumer health categories.
